VisionCare Macular Degeneration Implant Needs Post-Market Studies – Panel
This article was originally published in The Gray Sheet
Executive Summary
VisionCare Ophthalmic Technologies' IMT implantable miniature telescope should be approved to treat vision loss associated with end-stage, age-related macular degeneration, contingent upon two post-market studies, according to FDA's Ophthalmic Devices Panel
You may also be interested in...
Macular Degeneration Implant Approval Requires Two Post-Market Studies
VisionCare Ophthalmic Technologies must conduct two post-market studies of its IMT implantable miniature telescope as a condition of its July 1 PMA approval for end-stage age-related macular degeneration (AMD)
Macular Degeneration Implant Approval Requires Two Post-Market Studies
VisionCare Ophthalmic Technologies must conduct two post-market studies of its IMT implantable miniature telescope as a condition of its July 1 PMA approval for end-stage age-related macular degeneration (AMD)
FDA Panel Votes Down VisionCare Eye Prosthetic; Firm To Submit More Data
VisionCare Ophthalmic Technologies says it will provide to FDA additional data from its study of the Implantable Miniature Telescope (IMT) as requested by the agency's Ophthalmic Devices Panel